[1. Ferreres JR, Macaya A, Jucgla A, Muniesa C, Prats C, Peyri J. Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol Venereol. 2006;20:877-8.10.1111/j.1468-3083.2006.01552.x]Search in Google Scholar
[2. Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanol J Rare Dis. 2008;3:32- 48.10.1186/1750-1172-3-32]Search in Google Scholar
[3. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, Kerl H. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2007;157(Suppl 2):47-51.10.1111/j.1365-2133.2007.08273.x]Search in Google Scholar
[4. Ortega Garcia de Amezaga A, Garcia Arregui O, Yepeda Nuno S, Acha Sagredo A, Aguirre Urizar JM. Gorlin-Goltz syndrome: clinicopathologic aspects. Med Oral Patol Oral Cir Bucal. 2008;13(6):E338-43.]Search in Google Scholar
[5. Dierks C. Small molecules in oncology: GDC-0449: targeting the hedgehog signaling pathway. Recent Results in Cancer Res. 2010;184:235-8.10.1007/978-3-642-01222-8_17]Search in Google Scholar
[6. Bree AF, Shah MR, BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet. 2011;155A (9):2091-7.10.1002/ajmg.a.34128]Search in Google Scholar
[7. Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69:299-308.10.1002/(SICI)1096-8628(19970331)69:3<299::AID-AJMG16>3.0.CO;2-M]Search in Google Scholar
[8. Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30:460-4.10.1136/jmg.30.6.460]Search in Google Scholar
[9. Jones EA, Sajid MI, Shenton A, Evans DG. Basal cell carcinomas in Gorlin syndrome: a review of 202 patients. J Skin Cancer. 2011;2011:217378.10.1155/2011/217378]Search in Google Scholar
[10. Kimonis VE, Singh KE, Zhong R, Pastakia B, Digiovanna JJ, Bale SJ. Clinical and radiological features in young individuals with nevoid basal cell carcinoma syndrome. Genet Med. 2013;15:79-83.10.1038/gim.2012.96]Search in Google Scholar
[11. Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib: a syndrome. N Engl J Med. 1960;262:908-12.10.1056/NEJM196005052621803]Search in Google Scholar
[12. Jarisch W. Zur Lehre von den Hautgeschwulsten. Arch Dermatol Syphilol. 1894;28:162-222.10.1007/BF01843725]Search in Google Scholar
[13. White JC. Multiple benign cystic epitheliomas. J Cutan Genitourin Dis. 1894;12:477-84.]Search in Google Scholar
[14. Binkley GW, Johnson HH. Epithelioma adenoides cysticum: basal cell nevi, agenesis of the corpus callosum and dental cysts: a clinical and autopsy study. AMA Arch Dermatol Syphiol. 1951;63:73-84.10.1001/archderm.1951.01570010076006]Search in Google Scholar
[15. Gorlin RJ, Yunis JJ, Tuna N. Multiple nevoid basal cell carcinoma, odontogenic keratocysts and skeletal anomalies: a syndrome. Acta Derm Venereol. 1963;43:39-55.]Search in Google Scholar
[16. Gorlin RJ, Vickers RA, Kelln E, Williamson JJ. Multiple basal cell nevi syndrome. An analysis of a syndrome consisting of multiple nevoid basal-cell carcinoma, jaw cysts, skeletal anomalies, medulloblastoma, and hyporesponsiveness to parathormone. Cancer 1965;18:89-104.10.1002/1097-0142(196501)18:1<89::AID-CNCR2820180114>3.0.CO;2-9]Search in Google Scholar
[17. Jawa DS, Sircar K, Somani R, Grover N, Jaidka S, Singh S. Gorlin-Goltz syndrome. J Oral Maxillofac Pathol. 2009;13:89-92.10.4103/0973-029X.57677]Search in Google Scholar
[18. Patil KV, Mahima G, Gupta B. Gorlin syndrome: a case report. J Indian Soc Pedod Prev Dent. 2005;23:198-203.10.4103/0970-4388.19010]Search in Google Scholar
[19. Shivaswamy KN, Sumathy TK, Shyamprasad AL, Ranganathan C. Gorlin syndrome or basal cell nevus syndrome (BCNS): a case report. Dermatol Online J. 2010;16(9):6.10.5070/D39033W6FH]Search in Google Scholar
[20. Kohli M, Kohli M, Sharma N, Siddiqui SR, Tulsi SP. Gorlin- Goltz syndrome. Natl J Maxillofac Surg. 2010;1(1):50-2.10.4103/0975-5950.69171]Search in Google Scholar
[21. Blackburn EH. Cancer interception. Cancer Prev Res (Phila). 2011;4:787-92.10.1158/1940-6207.CAPR-11-0195]Search in Google Scholar
[22. Casaroto AR, Loures DC, Moreschi E, Veltrini VC, Trento CL, Gottardo VD, et al. Early diagnosis of Gorlin-Goltz syndrome: case report. Head Face Med. 2011;7:2.10.1186/1746-160X-7-2]Search in Google Scholar
[23. Leonardi R, Santarelli A, Barbato E, Ciavarella D, Bolouri S, Harle F, et al. Atlanto-occipital ligament calcification: a novel sign in nevoid basal cell carcinoma syndrome. Anticancer Res. 2010;30(10):4265-7.]Search in Google Scholar
[24. Pinto LSS, Carlos-Bregni R, Junior HM, Filho MRM, Azanero WD, Leon JE, et al. Nevoid basal cell carcinoma syndrome: an analysis of four familial and two sporadic cases. J Oral Diag. 2012;1(1):20-5.]Search in Google Scholar
[25. Yordanova I, Gospodinov D, Kirov V, Pavlova V, Radoslavova G. A familial case of Gorlin-Goltz syndrome. J IMAB - Ann Proceed (Scient Papers). 2007;13(1):63-7.]Search in Google Scholar
[26. Potaznik D, Steinherz P. Multiple nevoid basal cell carcinoma syndrome and Hodgkin’s disease. Cancer. 1984;53(12):2713-5.10.1002/1097-0142(19840615)53:12<2713::AID-CNCR2820531226>3.0.CO;2-Z]Search in Google Scholar
[27. Zvulunov A, Strother D, Zirbel G, Rabinowitz LG, Esterly NB. Nevoid basal cell carcinoma syndrome. Report of a case with associated Hodgkin’s disease. J Pediatr Hematol Oncol. 1995;17(1):66-70.10.1097/00043426-199502000-000127743241]Search in Google Scholar
[28. Penel N, Robin YM, Mallet Y, Gauthier H, Vanseymortier L. Association head and neck angiosarcoma and nevoid basal cell carcinoma syndrome (Gorlin syndrome). Oral Oncol Extra. 2005;41:289-91.10.1016/j.ooe.2005.07.004]Search in Google Scholar
[29. Pereira CM, Lopes AM, Meneghini AJ, Silva AF, Botelho TdeL. Oral diffuse B-cell non-Hodgkin’s lymphoma associated to Gorlin-Goltz syndrome: a case report with one year followup. Indian J Pathol Microbiol. 2011;54:388-90.10.4103/0377-4929.8164921623100]Search in Google Scholar
[30. Schulz-Butulis BA, Gilson R, Farley M, Keeling JH. Nevoid basal cell carcinoma syndrome and non-Hodgkin’s lymphoma. Cutis. 2000;66:35-8.]Search in Google Scholar
[31. Mitropoulos P, Norman R. Nevoid basal cell carcinoma syndrome (Gorlin syndrome): updated review of minimally invasive treatments. Cutis. 2008;81:53-60.]Search in Google Scholar
[32. Neville JA, Williford PM, Jorizzo JL. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol. 2007;6(9):910-4.]Search in Google Scholar
[33. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg. 2006;32(1):63-9.10.1097/00042728-200601000-00011]Search in Google Scholar
[34. Torres A, Niemeyer A, Berkes B, Marra D, Schanbacher C, Gonzalez S, et al. 5% imiquimod cream and reflectancemode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg. 2004;30(12 Pt 1):1462-9.10.1111/j.1524-4725.2004.30504.x15606733]Search in Google Scholar
[35. Weis SE. Current treatment options for management of anal intraepithelial neoplasia. Onco Targets Ther. 2013;10(6):651-65.10.2147/OTT.S38217368422023788834]Search in Google Scholar
[36. Beach DF, Somer R. Novel approach to Gorlin syndrome: a patient treated with oral capecitabine. J Clin Oncol. 2011;29(14):e397-401.10.1200/JCO.2010.33.339321357787]Search in Google Scholar
[37. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma. A systematic review. Arch Dermatol. 2009;145(12):1431-8.10.1001/archdermatol.2009.29120026854]Search in Google Scholar
[38. Thissen MR, Kuijpers DI, Krekels GA. Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases. J Drugs Dermatol. 2006;5(5):461-4.]Search in Google Scholar
[39. Doctoroff A, Oberlender SA, Purcell SM. Full-face carbon dioxide laser resurfacing in the management of a patient with the nevoid basal cell carcinoma syndrome. Dermatol Surg. 2003;29(12):1236-40.]Search in Google Scholar
[40. Alessi SS, Sanches JA, Oliveira WR, Messina MC, Pimentel ER, Festa Neto C. Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream. Clinics (Sao Paulo). 2009;64(10):961-6.10.1590/S1807-59322009001000005276307019841702]Search in Google Scholar
[41. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg. 2000;26(6):577-9.10.1046/j.1524-4725.2000.00003.x10848940]Search in Google Scholar
[42. Micali G, Lacarrubba F, Nasca MR, De Pasquale R. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin’s syndrome. Clin Exp Dermatol. 2003;28 (Suppl 1):19-23.10.1046/j.1365-2230.28.s1.7.x]Search in Google Scholar
[43. Micali G, De Pasquale R, Caltabiano R, Impallomeni R, Lacarrubba F. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report. J Dermatol Treat. 2002;13(3):123-7.10.1080/09546630260199488]Search in Google Scholar
[44. Vereecken P, Monsieur E, Petein M, Heenen M. Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome. J Dermatolog Treat. 2004;15(2):120-1.10.1080/09546630310017825]Search in Google Scholar
[45. Amon RB, Goodkin PE. Topical 5-fluorouracil and the basalcell- nevus syndrome. N Engl J Med. 1976;295(12):677-8.10.1056/NEJM197609162951217]Search in Google Scholar
[46. Strange PR, Lang PG Jr. Long-term management of basal cell nevus syndrome with topical tretinoin and 5-fluorouracil. J Am Acad Dermatol. 1992;27(5 Pt 2):842-5.10.1016/0190-9622(92)70262-E]Search in Google Scholar
[47. Van Ruth S, Jansman FG, Sanders CJ. Total body topical 5-fluorouracil for extensive non-melanoma skin cancer. Pharm World Sci. 2006;28(3):159-62.10.1007/s11096-006-9030-x]Search in Google Scholar
[48. Cristofolini M, Zumiani G, Scappini P, Piscioli F. Aromatic retinoid in the chemoprevention of the progression of nevoid basal-cell carcinoma syndrome. J Dermatol Surg Oncol. 1984;10(10):778-81.10.1111/j.1524-4725.1984.tb01181.x]Search in Google Scholar
[49. Goldberg LH, Hsu SH, Alcalay J. Effectiveness of isotretinoin in preventing the appearance of basal cell carcinomas in basal cell nevus syndrome. J Am Acad Dermatol. 1989;21(1):144-5.10.1016/S0190-9622(89)80359-7]Search in Google Scholar
[50. Lien MH, Sondak VK. Nonsurgical treatment options for basal cell carcinoma. J Skin Cancer. 2011; 2011: 571734.]Search in Google Scholar
[51. Shumack S, Rigel D. Treatment of non-melanoma skin cancer: immunotherapy. Acta Derm Venereol Suppl. 2003;214:18-22.]Search in Google Scholar
[52. Stockfleth E, Ulrich C, Hauschild A, Lischner S, Meyer T, Christophers E. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol. 2002;12(6):569-72.]Search in Google Scholar
[53. Tillman DK,. Carroll MT. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J Drugs Dermatol. 2008;7(Suppl 1):s7-14.]Search in Google Scholar
[54. Tillman DK Jr, Carroll MT. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience. Cutis. 2007;79(3):241-8.]Search in Google Scholar
[55. Wu JK, Oh C, Strutton G, Siller G. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol. 2006;47(1):46-8.10.1111/j.1440-0960.2006.00222.x16405483]Search in Google Scholar
[56. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehiclecontrolled studies.J Am Acad Dermatol. 2004;50(5):722-33.10.1016/j.jaad.2003.11.06615097956]Search in Google Scholar
[57. Slade HB, Owens ML, Tomai M, Miller RL. Imiquimod 5% cream (Aldara). Expert Opin Investig Drugs. 1998;7(3):437-49.10.1517/13543784.7.3.43715991984]Search in Google Scholar
[58. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114(1):135-41.10.1046/j.1523-1747.2000.00833.x10620129]Search in Google Scholar
[59. Cozzi SJ, Le TT, Ogbourne SM, James C, Suhrbier A. Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice. Arch Dermatol Res. 2013;305(1):79-83.10.1007/s00403-012-1270-0353535622871992]Search in Google Scholar
[60. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30(30):3734-45. 10.1200/JCO.2012.41.868123008293]Search in Google Scholar